Production (Stage)
CervoMed Inc.
CRVO
$7.26
$0.141.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.31M | 9.74M | 10.07M | 9.65M | 8.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.31M | 9.74M | 10.07M | 9.65M | 8.08M |
| Cost of Revenue | 17.05M | 15.03M | 10.79M | 7.46M | 7.46M |
| Gross Profit | -7.74M | -5.29M | -728.10K | 2.19M | 623.10K |
| SG&A Expenses | 9.42M | 9.17M | 8.97M | 9.17M | 7.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.24M | 27.97M | 23.53M | 20.40M | 17.07M |
| Operating Income | -20.94M | -18.23M | -13.47M | -10.75M | -8.98M |
| Income Before Tax | -18.67M | -16.29M | -11.95M | -5.04M | -4.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.67 | -16.29 | -11.95 | -5.04 | -4.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.67M | -16.29M | -11.95M | -5.04M | -4.15M |
| EBIT | -20.94M | -18.23M | -13.47M | -10.75M | -8.98M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.14 | -1.99 | -1.60 | -0.40 | -2.89 |
| Normalized Basic EPS | -1.34 | -1.24 | -1.00 | -0.25 | -1.80 |
| EPS Diluted | -2.15 | -1.99 | -1.60 | -1.75 | -4.23 |
| Normalized Diluted EPS | -1.34 | -1.24 | -1.00 | -0.30 | -1.85 |
| Average Basic Shares Outstanding | 34.82M | 32.28M | 29.85M | 24.45M | 16.27M |
| Average Diluted Shares Outstanding | 34.82M | 32.28M | 29.85M | 24.91M | 16.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |